G-BA assessment of orphan drug gene therapies, Zolgensma and Libmeldy
The gene therapies Zolgensma and Libmeldy, both, are targeting very rare, severe, genetic diseases in children. The G-BA has now assessed the
Category: News and updates
Reimbursement price and discounts – Drug prices in Germany
You might be familiar with the price negotiations to derive the reimbursement price, but this does not always reflect the final, real-world
Another reimbursement restriction in Germany
Most medicines are reimbursed at 100% from the day of launch in Germany, i.e. coverage by SHI funds is granted with the marketing authorization
Why did the G-BA assess Trimbow now?
Trimbow was launched onto the German market in 2017. So why did the G-BA assess its benefit now? You likely know that
Change in morbidity factor means more GPs are needed in Germany
Identifying amount of required healthcare The G-BA developed the needs planning directive (German: Bedarfsplanungs-Richtlinie) to give national rules on “how much” SHI-funded